A COST-UTILITY ANALYSIS ON THE USE OF TRASTUZUMAB plus ANASTROZOLE COMPARED TO LAPATINIB plus LETROZOLE, LETROZOLE MONOTHERAPY OR ANASTROZOLE MONOTHERAPY IN THE TREATMENT OF HER2+/HORMONE RECEPTOR POSITIVE (HR plus ) METASTATIC BREAST CANCER (MBC) FROM THE PERSPECTIVE OF THE UK NATIONAL HEALTH SERVICE (NHS)

被引：0
|
作者：
McNamara, S. [1 ]
Moore, L. [1 ]
Ray, J. [2 ]
机构：
[1] Roche Prod Ltd, Welwyn Garden City AL7 3AY, Herts, England
[2] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A269 / A269
页数：1
相关论文
共 50 条
  • [21] Trastuzumab plus anastrozole prolongs progression-free survival in postmenopausal women with HER2-positive, hormone-dependent metastatic breast cancer (MBC)
    Kaufman, Bella
    Mackey, John
    Clemens, Michael
    Bapsy, Poonamalle
    Vaid, Ashok
    Wardley, Andrew
    Tjulandin, Sergei
    Jahn, Michaela
    Lehle, Michaela
    Jones, Alison
    ANNALS OF ONCOLOGY, 2006, 17
  • [22] Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - Results of the eLEcTRA trial
    Huober, J.
    Fasching, P. A.
    Barsoum, M.
    Petruzelka, L.
    Wallwiener, D.
    Thomssen, C.
    Reimer, T.
    Paepke, S.
    Azim, H. A.
    Ragosch, V.
    Kubista, E.
    Baumgaertner, A. K.
    Beckmann, M. W.
    May, C.
    Nimmrich, I.
    Harbeck, N.
    BREAST, 2012, 21 (01): : 27 - 33
  • [23] Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
    Kahraman, Seda
    Erul, Enes
    Seyyar, Mustafa
    Gumusay, Ozge
    Bayram, Ertugrul
    Demirel, Burcin Cakan
    Acar, Omer
    Aksoy, Sercan
    Baytemur, Naziyet Kose
    Sahin, Elif
    Cabuk, Devrim
    Basaran, Gul
    Paydas, Semra
    Yaren, Arzu
    Guven, Deniz Can
    Erdogan, Atike Pinar
    Demirci, Umut
    Yasar, Alper
    Bayoglu, Ibrahim Vedat
    Hizal, Mutlu
    Gulbagci, Burcu
    Paksoy, Nail
    Davarci, Sena Ece
    Yilmaz, Funda
    Dogan, Ozlem
    Orhan, Sibel Oyucu
    Kayikcioglu, Erkan
    Aytac, Ali
    Keskinkilic, Merve
    Mocan, Eda Eylemer
    Unal, Olcun Umit
    Aydin, Esra
    Yucel, Hakan
    Isik, Deniz
    Eren, Onder
    Uluc, Basak Oyan
    Ozcelik, Melike
    Hacibekiroglu, Ilhan
    Aydiner, Adnan
    Demir, Hacer
    Oksuzoglu, Berna
    Cilbir, Ebru
    Cubukcu, Erdem
    Cetin, Bulent
    Oktay, Esin
    Erol, Cihan
    Okutur, Sadi Kerem
    Yildirim, Nilgun
    Alkan, Ali
    Selcukbiricik, Fatih
    FUTURE ONCOLOGY, 2023, : 727 - 736
  • [24] Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
    Zhang, Pin
    Zhang, Qingyuan
    Tong, Zhongsheng
    Sun, Tao
    Li, Wei
    Ouyang, Quchang
    Hu, Xichun
    Cheng, Ying
    Yan, Min
    Pan, Yueyin
    Teng, Yuee
    Yan, Xi
    Wang, Ying
    Xie, Weimin
    Zeng, Xiaohua
    Wang, Xiaojia
    Hu, Changlu
    Geng, Cuizhi
    Zhang, Hongwei
    Li, Wenxin
    Wu, Xinhong
    Zhong, Jincai
    Xu, Jingwei
    Shi, Yanxia
    Wei, Wenhua
    Bayaxi, Nayima
    Zhu, Xiaoyu
    Xu, Binghe
    LANCET ONCOLOGY, 2023, 24 (06): : 646 - 657
  • [25] COST EFFECTIVENESS OF RIBOCICLIB PLUS LETROZOLE VERSUS PALBOCICLIB PLUS LETROZOLE FOR THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER FROM A US PRIVATE THIRD-PARTY PAYER PERSPECTIVE
    Suri, G.
    Mistry, R.
    Young, K. C.
    Hettle, R.
    May, J. R.
    Brixner, D.
    Oderda, G.
    Biskupiak, J.
    Tang, D.
    Bhattacharyya, D.
    Bhattacharyya, S.
    Mishra, D.
    Dalal, A.
    VALUE IN HEALTH, 2017, 20 (09) : A436 - A436
  • [26] registHER: Patient characteristics, treatment patterns, and preliminary outcomes in patients with HER2-positive (HER2+), hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Yardley, D. A.
    Kaufman, P. A.
    Mayer, M.
    Yood, M. Ulcickas
    Tan-Chiu, E.
    Brufsky, A. M.
    Rugo, H. S.
    Tripathy, D.
    Paik, S.
    Brammer, M. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [27] Cost-utility analysis of anastrozole versus tamoxifen as adjuvant therapy in postmenopausal women with early breast cancer (EBC): A UK National Health Service (NHS) perspective
    Brown, R
    Benedict, A
    Mansel, RE
    VALUE IN HEALTH, 2004, 7 (06) : 670 - 670
  • [28] An Exploration of the Association of Quality-of-Life(QOL) Scores with Tumor Progression Status in First Line Hormone Receptor Positive, HER2+Metastatic Breast Cancer (MBC) Patients Treated with Lapatinib Plus Letrozole or Letrozole Alone
    Sherrill, B.
    Amonkar, M. M.
    Sherif, B. N.
    Maltzman, J.
    O'Rourke, L.
    Johnston, S.
    CANCER RESEARCH, 2009, 69 (24) : 801S - 801S
  • [29] COST-EFFECTIVENESS OF RIBOCICLIB PLUS LETROZOLE COMPARED TO PALBOCICLIB PLUS LETROZOLE IN THE FIRST-LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) ADVANCED OR METASTATIC BREAST CANCER (ABC): A BRAZILIAN PRIVATE PAYER PERSPECTIVE
    Buehler, A.
    Kim, H. S. J.
    Fahham, L.
    Dionne, P. A.
    Castilho, G.
    VALUE IN HEALTH, 2019, 22 : S466 - S467
  • [30] Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+advanced or metastatic breast cancer(MBC)
    Riemsma, Rob
    Forbes, Carol A.
    Amonkar, Mayur M.
    Lykopoulos, Konstantinos
    Diaz, Jose R.
    Kleijnen, Jos
    Rea, Daniel W.
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (08) : 1263 - 1279
12345